FendX Discusses Recent CDC Report on the Rise of Six Superbug Infections in the US
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) highlights a new CDC report showing a 20% increase in infections from six antibiotic-resistant bacteria ('superbugs') in 2021 and 2022 compared to 2019. The CDC attributes this rise partly to COVID-19's impact on healthcare systems, longer hospital stays, and antibiotic overuse.
The report emphasizes the need for more effective infection prevention and control strategies. FendX, a nanotechnology company developing surface protection coatings, aims to contribute to reducing superbug spread. Dr. Carolyn Myers, CEO of FendX, states that the company is dedicated to developing innovative high-touch surface protection solutions to combat superbug transmission and enhance safety.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) mette in evidenza un nuovo rapporto del CDC che mostra un aumento del 20% delle infezioni causate da sei batteri resistenti agli antibiotici ('superbatteri') nel 2021 e 2022 rispetto al 2019. Il CDC attribuisce questo aumento in parte all'impatto del COVID-19 sui sistemi sanitari, ai soggiorni più lunghi in ospedale e all'uso eccessivo di antibiotici.
Il rapporto sottolinea la necessità di strategie di prevenzione e controllo delle infezioni più efficaci. FendX, un'azienda di nanotecnologia che sviluppa rivestimenti protettivi per superfici, si propone di contribuire a ridurre la diffusione dei superbatteri. La Dr.ssa Carolyn Myers, CEO di FendX, afferma che l'azienda è dedicata allo sviluppo di soluzioni innovative per la protezione delle superfici a contatto frequente per combattere la trasmissione dei superbatteri e migliorare la sicurezza.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) destaca un nuevo informe de los CDC que muestra un aumento del 20% en infecciones por seis bacterias resistentes a los antibióticos ('superbacterias') en 2021 y 2022 en comparación con 2019. El CDC atribuye este aumento en parte al impacto del COVID-19 en los sistemas de salud, estancias hospitalarias más prolongadas y el uso excesivo de antibióticos.
El informe enfatiza la necesidad de estrategias de prevención y control de infecciones más efectivas. FendX, una empresa de nanotecnología que desarrolla recubrimientos de protección para superficies, busca contribuir a la reducción de la propagación de superbacterias. La Dra. Carolyn Myers, CEO de FendX, afirma que la empresa está dedicada a desarrollar soluciones innovadoras para la protección de superficies de alto contacto para combatir la transmisión de superbacterias y mejorar la seguridad.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)는 CDC의 새로운 보고서를 강조하며 2019년과 비교하여 2021년과 2022년 동안 여섯 가지 항생제 내성 박테리아('슈퍼박테리아') 감염이 20% 증가했다고 밝혔습니다. CDC는 이 증가의 일부를 COVID-19의 영향으로 인한 의료 시스템의 변화, 병원에 더 오래 입원하는 것, 항생제의 과도한 사용에 기인한다고 설명합니다.
이 보고서는 보다 효과적인 감염 예방 및 통제 전략의 필요성을 강조합니다. 나노기술 기업인 FendX는 표면 보호 코팅을 개발하고 있으며, 슈퍼박테리아의 확산을 줄이는 데 기여하는 것을 목표로 합니다. FendX의 CEO인 Carolyn Myers 박사는 회사가 슈퍼박테리아 전파를 방지하고 안전성을 높이기 위한 혁신적인 고접촉 표면 보호 솔루션을 개발하는 데 전념하고 있다고 말했습니다.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) souligne un nouveau rapport des CDC montrant une augmentation de 20% des infections par six bactéries résistantes aux antibiotiques ('superbactéries') en 2021 et 2022 par rapport à 2019. Les CDC attribuent cette hausse en partie à l'impact du COVID-19 sur les systèmes de santé, les séjours hospitaliers prolongés et le surutilisation des antibiotiques.
Le rapport met l'accent sur la nécessité de stratégies de prévention et de contrôle des infections plus efficaces. FendX, une entreprise de nanotechnologie développant des revêtements de protection pour surfaces, vise à contribuer à la réduction de la propagation des superbactéries. Dr. Carolyn Myers, CEO de FendX, déclare que l'entreprise est dédiée au développement de solutions innovantes de protection des surfaces à fort contact pour lutter contre la transmission des superbactéries et améliorer la sécurité.
FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) hebt einen neuen CDC-Bericht hervor, der einen Anstieg von 20% bei Infektionen durch sechs antibiotikaresistente Bakterien ('Superbugs') im Jahr 2021 und 2022 im Vergleich zu 2019 zeigt. Die CDC führt diesen Anstieg teilweise auf die Auswirkungen von COVID-19 auf die Gesundheitssysteme, längere Krankenhausaufenthalte und den übermäßigen Einsatz von Antibiotika zurück.
Der Bericht betont die Notwendigkeit effektiverer Präventions- und Kontrollstrategien für Infektionen. FendX, ein Unternehmen für Nanotechnologie, das Oberflächenschutzbeschichtungen entwickelt, verfolgt das Ziel, zur Reduzierung der Verbreitung von Superbugs beizutragen. Dr. Carolyn Myers, CEO von FendX, erklärt, dass das Unternehmen sich der Entwicklung von innovativen Lösungen zum Schutz von stark beanspruchten Oberflächen widmet, um die Übertragung von Superbugs zu bekämpfen und die Sicherheit zu erhöhen.
- FendX is developing nanotechnology-based surface protection coatings to reduce pathogen spread
- The company's focus aligns with the CDC's call for innovative prevention strategies against superbugs
- The CDC reports a 20% increase in infections from six antibiotic-resistant bacteria in 2021 and 2022 compared to 2019
- The rise in superbug infections indicates a challenging market environment for infection control solutions
CDC reports burden of six hard-to-treat superbugs increased by a combined
CDC call to action for more effective infection prevention and control, and the need for innovative prevention strategies
FendX's goal is to develop innovative solutions using their nanotechnology that will contribute to reducing the spread of superbugs
Oakville, Ontario--(Newsfile Corp. - July 30, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), a nanotechnology company developing surface protection coatings to reduce the spread of pathogens, highlights a new report from the Centre of Disease Control ("CDC") published on July 16, 2024 highlighting the increased incidence of infections caused by six antibiotic-resistant bacteria (commonly know as 'superbugs') and emphasized the need to invest in the prevention-focused public health initiatives that can effectively control their spread.
The new CDC report highlighted a combined
Dr. Carolyn Myers, CEO and President of FendX states, "This CDC report reinforces the difficulty of controlling infections rates caused by superbugs and that a focus on infection control and new innovations is needed. At FendX, we are dedicated to developing innovative high-touch surface protection product solutions to reduce the spread of superbugs." Dr. Myers continues, "Our goal is to actively contribute to the fight against superbug transmission and make peoples lives safer."
About FendX Technologies Inc.
FendX is a Canada-based nanotechnology company focused on developing products to make people's lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has exclusive worldwide licenses to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.
ON BEHALF OF FENDX TECHNOLOGIES INC.
"Carolyn Myers"
Carolyn Myers
Chief Executive Officer and Director
Contacts:
Dr. Carolyn Myers, CEO and Director
1-800-344-9868
investor@fendxtech.com
For more information, please visit https://fendxtech.com and the Company's profile on SEDAR+ at www.sedarplus.ca.
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release
Forward-Looking Statements
This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; the Company's goal of developing innovative high-touch surface protection product solutions to reduce the spread of superbugs and make peoples lives safer; the Company's plans to develop new technologies to reduce the spread of pathogens; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "potential," "goal," "objective," "prospective," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and involve several risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements.
Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history; research and development activities; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other risk factors set forth in the Company's public filings which are available on SEDAR+ at www.sedarplus.ca. Accordingly, the reader is urged to refer to the Company's such filings for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors should change.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218132
FAQ
What did the recent CDC report reveal about superbug infections in the US?
How is FendX Technologies (FDXTF) addressing the rise in superbug infections?
What factors contributed to the increase in superbug infections according to the CDC?
What is the CDC's recommendation to combat the rise in superbug infections?
